In a report published Monday, Jefferies analyst Biren Arnin reiterated a Hold rating on Regeneron Pharmaceuticals REGN, and raised the price target from $179.00 to $247.00.
In the report, Arnin noted, “REGN reported a top-line beat driven by U.S. Eylea sales leading to slightly raised guidance. Given the recent strength in REGN shares attributed to Avastin cmpding issues, there appeared to be very little shift away from Avastin. We have, however, raised our PT to $247 largely due to increased traction in ex-U.S. Eylea sales and the value for PIII alirocumab for hypercholesterolemia.”
Regeneron Pharmaceuticals closed on Friday at $248.63.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in